Skip to Main Content

Drug discovery is long and winding, and riddled with high-cost failure at every turn. A newly unveiled Cambridge startup aims to streamline the process with a platform it’s calling “CRISPRomics” — and it has recruited some top-flight talent to lead the effort.

The two-year-old company — KSQ Therapeutics — just emerged from stealth, announcing a $76 million financing round and a new CEO: Dr. David Meeker, former chief executive of Genzyme. He stepped down from his post at the merged Sanofi-Genzyme (SNY) this past April.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!